SGMO

0.787

3.42% -0.0279

Dopo l'orario di chiusura: .79 0.003 +0.38%

Sangamo Therapeutics Inc (SGMO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$0.8149

Aprire:

$0.8

Volume 24 ore:

1.98M

Relative Volume:

0.31

Capitalizzazione di mercato:

$165.39M

Reddito:

$52.29M

Utile/perdita netta:

$-134.84M

Rapporto P/E:

-1.0493

EPS:

-0.75

Flusso di cassa netto:

$-117.11M

1 W Prestazione:

+11.54%

1M Prestazione:

-6.22%

6M Prestazione:

-47.53%

1 anno Prestazione:

+56.46%

Intervallo 1D:

$0.77

$0.8299

Intervallo di 1 settimana:

$0.70

$0.84

Portata 52W:

$0.304

$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Nome

Sangamo Therapeutics Inc

Settore

Healthcare (1154)

Industria

Biotechnology (677)

Telefono

(510) 970-6000

Indirizzo

501 CANAL BLVD., RICHMOND, CA

Dipendente

183

Cinguettio

@sangamotx

Prossima data di guadagno

2025-03-17

Ultimi documenti SEC

SGMO's Discussions on Twitter

Confronta SGMO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SGMO Sangamo Therapeutics Inc	0.787	165.39M	52.29M	-134.84M	-117.11M	-0.75
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-13	Aggiornamento	Truist	Hold → Buy
2024-12-10	Reiterato	H.C. Wainwright	Buy
2023-11-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2023-04-28	Downgrade	BofA Securities	Neutral → Underperform
2023-02-27	Aggiornamento	Wedbush	Neutral → Outperform
2023-01-06	Downgrade	BofA Securities	Buy → Neutral
2022-06-13	Ripresa	Wedbush	Neutral
2021-05-04	Iniziato	RBC Capital Mkts	Outperform
2021-01-07	Ripresa	Guggenheim	Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-12-16	Ripresa	H.C. Wainwright	Buy
2020-09-08	Iniziato	BofA Securities	Buy
2020-07-07	Iniziato	SunTrust	Buy
2019-08-26	Iniziato	H.C. Wainwright	Buy
2018-11-14	Downgrade	JP Morgan	Overweight → Neutral
2018-11-09	Downgrade	Guggenheim	Buy → Neutral
2018-10-10	Iniziato	Guggenheim	Buy
2018-06-20	Iniziato	BofA/Merrill	Buy
2017-11-15	Aggiornamento	Piper Jaffray	Neutral → Overweight
2017-06-22	Ripresa	Jefferies	Buy
2016-11-01	Downgrade	Wedbush	Outperform → Neutral
2016-10-19	Downgrade	Piper Jaffray	Overweight → Neutral
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-10-23	Ripresa	Jefferies	Buy
2013-05-03	Iniziato	BioLogic Equity Research	Sell
2011-02-23	Reiterato	JMP Securities	Mkt Outperform
2010-07-29	Reiterato	Wedbush	Outperform
2009-10-19	Iniziato	Brean Murray	Sell
2009-10-07	Reiterato	Leerink Swann	Outperform
2009-08-25	Reiterato	JMP Securities	Mkt Outperform

Mostra tutto

Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie

Apr 22, 2025

Form 4Statement of changes in beneficial ownership of securities - ADVFN

Apr 22, 2025

Apr 15, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa

Apr 15, 2025

Apr 13, 2025

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com

Apr 04, 2025

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha

Apr 04, 2025

Sangamo Thera enters critical deal with Lilly - The Pharma Letter

Apr 04, 2025

Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace

Apr 04, 2025

Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum

Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025

Apr 03, 2025

RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga

Apr 03, 2025

Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025

Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada

Apr 03, 2025

Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals

Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener

Apr 03, 2025

Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga

Apr 03, 2025

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa

Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com

Apr 03, 2025

Apr 02, 2025